Regional success on screening and chemoprophylaxis in contacts of patients with pulmonary tuberculosis in Turkey: a dispensary experience in 2016-2017.


Journal

Transactions of the Royal Society of Tropical Medicine and Hygiene
ISSN: 1878-3503
Titre abrégé: Trans R Soc Trop Med Hyg
Pays: England
ID NLM: 7506129

Informations de publication

Date de publication:
01 06 2019
Historique:
received: 01 11 2018
revised: 21 01 2019
accepted: 07 02 2019
pubmed: 21 3 2019
medline: 27 6 2020
entrez: 21 3 2019
Statut: ppublish

Résumé

Turkey has a national tuberculosis (TB) control program that follows the standards set by the World Health Organization's (WHO) global TB control program. In this record-based retrospective study, contact screening and chemoprophylaxis of 469 TB contacts registered at the Samsun Tuberculosis Dispensary in 2016-2017 were assessed. On average, patients with pulmonary TB each had four contacts. Chemoprophylaxis was administered in 233 of the contacts for the following reasons: having close contact with an active TB patient (187 [80%]), being <15 y of age and tuberculin skin test (TST) positive (12 [5%]), detection of latent TB infection (27 [12%]) or not having been treated for TB before in conjunction with the discovery via radiography of a sequel lesion (7 [3%]). The remaining 236 contacts were not given chemoprophylaxis: 203 (86%) were TST negative, 10 (4%) rejected chemoprophylaxis and 23 (10%) refused to participate in an examination. Chemoprophylaxis was given to 30% of contacts in the first week and to 75% of contacts in the first month. The treatment completion rate was 80%, while the rate of chemoprophylaxis abandonment was 19.5% for males and 21.2% for females. The Samsun TB dispensary is successfully implementing the WHO's End TB strategy and has achieved higher treatment completion rates than other countries.

Sections du résumé

BACKGROUND
Turkey has a national tuberculosis (TB) control program that follows the standards set by the World Health Organization's (WHO) global TB control program.
METHODS
In this record-based retrospective study, contact screening and chemoprophylaxis of 469 TB contacts registered at the Samsun Tuberculosis Dispensary in 2016-2017 were assessed.
RESULTS
On average, patients with pulmonary TB each had four contacts. Chemoprophylaxis was administered in 233 of the contacts for the following reasons: having close contact with an active TB patient (187 [80%]), being <15 y of age and tuberculin skin test (TST) positive (12 [5%]), detection of latent TB infection (27 [12%]) or not having been treated for TB before in conjunction with the discovery via radiography of a sequel lesion (7 [3%]). The remaining 236 contacts were not given chemoprophylaxis: 203 (86%) were TST negative, 10 (4%) rejected chemoprophylaxis and 23 (10%) refused to participate in an examination. Chemoprophylaxis was given to 30% of contacts in the first week and to 75% of contacts in the first month. The treatment completion rate was 80%, while the rate of chemoprophylaxis abandonment was 19.5% for males and 21.2% for females.
CONCLUSIONS
The Samsun TB dispensary is successfully implementing the WHO's End TB strategy and has achieved higher treatment completion rates than other countries.

Identifiants

pubmed: 30892630
pii: 5406191
doi: 10.1093/trstmh/trz008
doi:

Substances chimiques

Antitubercular Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

351-355

Informations de copyright

© The Author(s) 2019. Published by Oxford University Press on behalf of Royal Society of Tropical Medicine and Hygiene. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Cihad Dundar (C)

Department of Public Health, Faculty of Medicine, Ondokuz Mayis University, Atakum/Samsun, Turkey.

Derya Oztomurcuk (D)

Samsun Tuberculosis Dispensary of Health Directorate, Samsun, Turkey.

Ozlem Terzi (O)

Department of Public Health, Faculty of Medicine, Ondokuz Mayis University, Atakum/Samsun, Turkey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH